Although the synthesized melanin was aggregated within one hour, the aggregation was inhibited by the addition of glutathione
In the Phase 2 obesity trial it produced about 24% weight loss at 12 mg over 48 weeks, the most of any drug in the class, and it cut liver fat by 86% in the people who started with fatty liver. In the 80-week Phase 3 obesity trial of 2,300 adults with an average BMI of 40, 12 mg produced 28% weight loss and 9 mg reached 26%
The closest alternative to BPC-157 for healing
Who Epithalon May Be For Epithalon may be a fit for: Adults focused on structured longevity planning who want conservative, physician-led protocol design Individuals with persistent sleep dysregulation where broader evaluation has been considered People who want to pair peptide protocols with appropriate diagnostics and follow-up Who Should Be Cautious Epithalon may not be appropriate if: Sleep symptoms are new, severe, or rapidly worsening without evaluation There is untreated obstructive sleep apnea, severe mood disorder symptoms, or significant neurologic concerns that need assessment first The goal is anti-aging outcomes without willingness to address fundamentals (sleep hygiene, stress load, training recovery, metabolic factors) A peptide protocol should not become a substitute for proper evaluation
Other enzymes using glutathione as a substrate are glutaredoxins
EINECS206-141-6
